Queensland Study Revives Immune Defenses Against Superbugs After 10 Years via HDAC6 Inhibition
Updated
Updated · Drug Target Review · May 15
Queensland Study Revives Immune Defenses Against Superbugs After 10 Years via HDAC6 Inhibition
11 articles · Updated · Drug Target Review · May 15
A 10-year University of Queensland study found an experimental HDAC6 inhibitor can restart mitochondrial fission in immune cells, restoring their ability to fight bacterial infections without directly attacking the microbes.
The mechanism targets a host process that some bacteria suppress to survive: once mitochondrial fission resumes, cells tap intracellular energy reserves and build antimicrobial lipid droplets that help clear infection.
Researchers showed the effect in mammalian cells and animal models, with Escherichia coli infection itself triggering the fission response that the treatment is designed to reinforce.
The work points to host-directed therapies as a potential alternative to conventional antibiotics as antimicrobial resistance worsens, including in hard-to-treat infections and sepsis.
With selective HDAC6 inhibitors showing promise in immune modulation, how soon might these therapies move from lab research to real-world treatment for deadly infections?
Could boosting your own immune cells by tweaking mitochondrial fission be the breakthrough answer to antibiotic-resistant superbugs?
What are the hidden risks or challenges of using host-directed therapies like mitochondrial fission activation to fight infections, and could this approach backfire?